Schrödinger outlines 10%-15% 2026 ACV growth as Bristol Myers Squibb deploys Bunsen (NASDAQ:SDGR)

Schrödinger (SDGR) reported robust Q2 2026 results with 27% annual contract value (ACV) growth, materially outpacing its forward guidance of 10%-15% for full-year 2026. This outperformance signals accelerating adoption of the company's computational drug discovery platform, particularly as enterprise clients deepen deployment. The stronger-than-expected trajectory suggests market demand for AI-driven molecular modeling tools remains robust despite macro headwinds.

The launch of Bunsen, a new AI capability, and deployment by Bristol Myers Squibb (BMY) represent strategic wins in the pharmaceutical vertical. BMY's adoption—a top-tier biopharma player—validates Schrödinger's technology for mission-critical R&D workflows and signals potential for expanded wallet share across the industry. Bunsen's positioning as a next-generation inference engine could accelerate time-to-discovery metrics, a high-value proposition for cash-intensive pharma programs.

The shift toward hosted infrastructure deployment reflects a maturation in Schrödinger's business model, improving recurring revenue quality and customer stickiness. This transition typically supports higher gross margins and more predictable cash generation, though it may require upfront investment in cloud infrastructure and support capabilities. Margin expansion becomes critical to justify current valuation multiples in growth-stage software.

Sector implication: The strength in computational life sciences suggests sustained institutional investment in biotech productivity tools and AI-augmented drug development. This positioning benefits Schrödinger within the broader Technology-Health Care crossover, though execution risks on profitability and competitive intensity from larger players (e.g., Schrodinger-scale entrants) remain material headwinds.